Loading
Latest filing published 17 Sept 2024 for T2 Biosystems, Inc., €120. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of David B. Elsbree in T2 Biosystems, Inc., where the filings describe the role as board member. Over a trading history stretching from 25 June 2021 to 13 September 2024, the count stands at 5 filings.
No open-market purchase appears, only 1 sale worth €120. The rest of the record consists of 4 option exercises. 2024 to date brings no purchases and 1 sale.
On 17 September 2024 came the latest disclosure, an open-market sale for €120 in T2 Biosystems, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations